| Intervention | NMA OR (95% CrI) | NMA LogOR (95% CrI) | Number of studies providing direct evidence |
|---|---|---|---|
| Misoprostol >600 mcg and ≤ 800 mcg | 0.000 (0.000, 0.178) | −67.24 (−153.2, −1.728) | - |
| Ergometrine plus oxytocin | 1.693 (0.166, 21.802) | 0.5265 (−1.797, 3.082) | - |
| Misoprostol plus oxytocin | 2.318 (0.588, 9.796) | 0.8407 (−0.531, 2.282) | 1 |
| Oxytocin >1 IU and ≤ 5 IU | 2.349 (0.329, 15.943) | 0.8539 (−1.111, 2.769) | 1 |
| Oxytocin unspecified dose | 3.083 (0.062, 221.850) | 1.126 (−2.777, 5.402) | 1 |
| Misoprostol ≤ 600 mcg | 6.110 (0.881, 61.992) | 1.81 (−0.1266, 4.127) | 1 |
| Oxytocin > 10 IU | 6.903 (1.978, 30.723) | 1.932 (0.6821, 3.425) | 5 |
| Oxytocin >5 IU and ≤ 10 IU | 11.001 (2.921, 58.440) | 2.398 (1.072, 4.068) | 4 |
Results from the random effects NMA. OR<1 favours the intervention (lower risk of transfusion in the intervention arm), OR>1 favours carbetocin, with larger numbers indicating a greater benefit of carbetocin in that comparison. Abbreviations: OR, odds ratio; CrI, credible interval.
From: Evidence reviews for uterotonics for the prevention of postpartum haemorrhage
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.